Dyne Therapeutics is making significant strides in treating genetically driven neuromuscular diseases, highlighted by positive long-term cardiopulmonary data from the Phase 1/2 DELIVER trial of z-rostudirsen in Duchenne muscular dystrophy (DMD), the initiation of the pivotal Phase 3 HARMONIA trial for z-basivarsen in myotonic dystrophy type 1 (DM1), and ongoing registrational efforts supporting potential accelerated approvals. These developments underscore the potential of the company’s FORCE platform to deliver meaningful functional improvements across muscle systems, including heart and lungs, while advancing toward commercialization in rare disease indications.
Dyne Therapeutics continues to build momentum in its mission to transform outcomes for patients with serious neuromuscular disorders through its proprietary FORCE platform, which enables targeted delivery of oligonucleotide payloads to muscle tissue and the central nervous system.
In Duchenne muscular dystrophy, the company recently presented new analyses from the ongoing Phase 1/2 DELIVER trial of z-rostudirsen (formerly DYNE-251) at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference. These analyses focused on 24-month data, revealing improvements in heart and lung function that contrast sharply with the expected natural history declines in DMD patients. Cardiopulmonary complications remain a major challenge in DMD, often contributing to disease progression and reduced quality of life. The observed stabilization or gains in cardiac and pulmonary metrics highlight the platform’s ability to reach critical muscles like the heart, diaphragm, and trunk, beyond skeletal muscle benefits previously reported.
Earlier topline results from the Registrational Expansion Cohort (REC) of DELIVER showed the trial met its primary endpoint, with a statistically significant increase in muscle content-adjusted dystrophin expression to 5.46% of normal at six months (p<0.0001), representing a seven-fold change from baseline. This level of dystrophin production has translated into unprecedented and sustained functional improvements in multiple domains, including upper and lower limb strength, as seen in pooled 18-month data from earlier cohorts. Z-rostudirsen has secured Breakthrough Therapy, Fast Track, and Rare Pediatric Disease designations from the FDA, along with Orphan Drug status in key regions, facilitating expedited development.
With the placebo-controlled portion of the REC completed, Dyne is preparing a Biologics License Application submission for U.S. Accelerated Approval in the second quarter of 2026, potentially enabling a launch as early as the first quarter of 2027 if priority review is granted. The company also plans to initiate a global confirmatory Phase 3 trial for z-rostudirsen in the second quarter of 2026 to support broader international approvals.
Shifting to myotonic dystrophy type 1, Dyne has advanced z-basivarsen (formerly DYNE-101) into a pivotal stage with the initiation of the Phase 3 HARMONIA trial. This global, randomized, placebo-controlled, double-blind study will enroll approximately 150 participants to evaluate efficacy, safety, and tolerability over 48 weeks, using a clinically meaningful functional measure as the primary endpoint. HARMONIA builds on positive data from the Phase 1/2 ACHIEVE trial, where long-term results demonstrated sustained improvements in function, strength, and overall disease burden as reported by both patients and physicians.
The ACHIEVE trial’s registrational expansion cohort continues to progress, with full enrollment expected in the second quarter of 2026. Video hand opening time serves as a key early indicator of clinical benefit for potential U.S. Accelerated Approval. Z-basivarsen holds Breakthrough Therapy, Fast Track, and Orphan Drug designations from the FDA, as well as Orphan Drug status from the EMA and Japan’s MHLW. Dyne aligned with regulators on the confirmatory Phase 3 design, positioning HARMONIA as a field-defining study that could demonstrate broad systemic benefits due to effective delivery to skeletal muscles and the CNS.
Beyond these lead programs, Dyne is expanding its DMD franchise with preclinical candidates targeting additional exon skipping opportunities, including exons 53, 45, 44, and 55. These molecules leverage the same FORCE platform chemistry to potentially address larger patient populations. Preclinical work in Pompe disease and facioscapulohumeral muscular dystrophy also continues, with data presentations reinforcing the platform’s versatility.
The company’s financial position supports these ambitious efforts, with substantial cash reserves enabling operations well into the future while funding ongoing trials, regulatory submissions, and potential commercial preparations.
Key regulatory and clinical milestones in the near term include the BLA submission for z-rostudirsen and continued enrollment progress in both lead programs.
Disclaimer: This article is for informational purposes only and does not constitute investment advice, medical advice, or a recommendation to buy or sell any securities. The information presented is based on publicly available data and should not be relied upon as the sole basis for any decision. Consult qualified professionals for personalized guidance.